Page last updated: 2024-10-31

modafinil and Parkinsonian Disorders

modafinil has been researched along with Parkinsonian Disorders in 5 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study."9.17Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013)
"To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study."5.17Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lohr, JB1
Liu, L1
Caligiuri, MP1
Kash, TP1
May, TA1
Murphy, JD1
Ancoli-Israel, S1
van Vliet, SA3
Vanwersch, RA3
Jongsma, MJ3
van der Gugten, J1
Olivier, B3
Philippens, IH3
van Vlieta, SA1
Blezer, EL1
Montastruc, JL1
Rascol, O1

Trials

1 trial available for modafinil and Parkinsonian Disorders

ArticleYear
Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
    Schizophrenia research, 2013, Volume: 150, Issue:1

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzhydryl Compounds; Cognition Disorders; Disord

2013

Other Studies

4 other studies available for modafinil and Parkinsonian Disorders

ArticleYear
Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
    Behavioural pharmacology, 2006, Volume: 17, Issue:5-6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Arousal; Benzhydryl Com

2006
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    Brain research, 2008, Jan-16, Volume: 1189

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke

2008
Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:5

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Callithrix; Disease Models, A

2008
Modafinil and pramipexole-associated somnolence.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants; Disor

2001